Michael Baker | Senior Director Viral Gene Therapy
FUJIFILM Biotechnologies

Currently, the majority of launched gene therapies have been in the rare disease space with small patient populations and relatively low doses. These processes have largely relied on transient production of the viral vectors at volumes below 2000L. Whilst this approach has enabled companies to get products to market, the resultant cost is prohibitively high when the curative potential of the therapy is not always met. This becomes even more problematic for mass market, high dose indications. Whilst developers are working to reduce dose requirements and improve efficacy, efforts are required throughout the industry to tackle this multifaceted problem. FUJIFILM Biotechnologies are working to develop a number of enabling technologies for the scale up and mass production of viral vectors. This talk will discuss how innovation within Fujifilm is being used to alleviate obstacles currently facing ATMP manufacturing from pre-clinical to commercial and beyond.